Loading...
•
Sep 30, 2023
Black Diamond Therapeutics Q3 2023 Earnings Report
Reported third quarter financial results and provided a corporate update.
Key Takeaways
Black Diamond Therapeutics reported its third quarter 2023 financial results. The company's cash, cash equivalents, and investments totaled $144.3 million as of September 30, 2023, which is expected to fund operations into the first half of 2025. BDTX-1535 Phase 1 dose escalation data showed durable anti-tumor activity and favorable safety profile in NSCLC patients. The first patient was dosed in a Phase 1 trial of BDTX-4933.
Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients.
BDTX-1535 NSCLC expansion cohorts are enrolling, with initial data expected in 2024.
Dosed first patient in a Phase 1 trial of BDTX-4933, a brain-penetrant RAF inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors.
Cash, cash equivalents, and investments of $144.3 million as of September 30, 2023, expected to be sufficient to fund operations into the first half of 2025.
Forward Guidance
Black Diamond believes its cash, cash equivalents and investments will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into the first half of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...